The Insurance Association of China (IAC) released a recommended drug list for commercial insurance, selecting an initial batch of 58 recommended drugs and medical devices. The list targets coverage gaps beyond China’s basic medical insurance, with 32 products – nearly 60% – being out‑of‑pocket drugs outside the National Reimbursement Drug List (NRDL), and 25 Class 1 innovative drugs together with 2 Class 2 modified new drugs accounting for nearly half of the selections.
List Snapshot
| Item | Detail |
|---|---|
| Issuing Body | Insurance Association of China (IAC) |
| Release Date | 10 November 2026 |
| Instrument | Recommended drug list for commercial insurance – integral component of the model medical insurance clauses |
| Initial Batch Size | 58 recommended drugs and medical devices |
| Innovation Composition | 25 Class 1 innovative drugs + 2 Class 2 modified new drugs (together nearly half of the list) |
| NRDL Status | 32 products (≈ 60 %) are out‑of‑pocket drugs outside the NRDL |
| Oncology Indications Covered | High‑incidence malignant tumors in China – lung cancer, liver cancer, hematologic malignancies |
| Rare Disease Coverage | Tumors in the National Rare Disease Catalogue, e.g., neuroblastoma |
| Coverage Scope | Specific out‑of‑hospital drugs and medical devices; usable alongside short‑term and long‑term model clauses for general commercial medical insurance |
| Update Mechanism | Timely evaluations and dynamic adjustments based on pharmaceutical innovation progress and changes in clinical applications |
| Individual Products / Prices | Not disclosed |
Coverage Logic & Selection Criteria
- Gap‑Filling Design: Compilation focused heavily on coverage needs outside the basic medical insurance catalogue – positioning commercial insurance as the payer layer for high‑value innovative therapies the NRDL has not yet absorbed.
- Multi‑Dimensional Evaluation: The IAC established a medical expert pool through open solicitation, and organized insurance companies alongside randomly selected medical and pharmaceutical experts to conduct professional evaluations centered on market demand, clinical value, and claims experience.
- Innovation‑Heavy Composition: With 25 Class 1 innovative drugs, the list tilts decisively toward newly approved, higher‑cost therapies – the segment where out‑of‑pocket burden is highest for Chinese patients.
- Rare Disease Inclusion: Coverage of National Rare Disease Catalogue tumors such as neuroblastoma extends protection to pediatric and ultra‑rare oncology populations typically excluded from mass‑market policies.
Development Timeline
| Date | Event |
|---|---|
| June 2025 | Work initiated, led by the Health Insurance Committee of the IAC, to formulate model clauses for medical insurance and the recommended drug list for commercial insurance |
| 2025–2026 | Expert pool established via open solicitation; insurers and randomly selected medical/pharmaceutical experts conduct multi‑dimensional evaluations |
| November 2026 | Initial batch of 58 recommended drugs and medical devices released as an integral component of the model medical insurance clauses |
Market Impact & Outlook
- Commercial Payer Expansion: By standardizing coverage of out‑of‑NRDL innovative drugs across the model clauses used by China’s commercial medical insurers, the list materially widens the non‑government payer pool for high‑priced oncology and rare‑disease therapies.
- Pharma Commercialization Tailwind: For sponsors of the 32 out‑of‑pocket products, inclusion in the recommended list can accelerate uptake through huimin‑bao–style and commercial medical policies, softening the revenue cliff between launch and NRDL negotiation.
- Dynamic Adjustment Signal: The IAC’s commitment to timely evaluations and dynamic adjustments – rationally incorporating more drugs with high market demand and clinical value – creates an ongoing, semi‑institutionalized pathway for innovative products to reach commercial coverage between NRDL cycles.
- Claims Standardization: Model clauses paired with a recommended list should reduce policy heterogeneity, simplify claims adjudication for out‑of‑hospital drug purchases, and improve claims experience – a stated evaluation criterion.
- Key Watch Items: Uptake of the model clauses by individual insurers, expansion of future batches, and whether NRDL‑listed products gain supplementary commercial coverage for indications beyond reimbursement scope – all not disclosed at release.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the IAC recommended drug list for commercial insurance, including dynamic adjustments, future list expansions, and market impact on insurers and pharmaceutical sponsors. Actual outcomes may differ due to risks including insurer adoption of the model clauses, evolution of clinical evidence and pricing, changes in NRDL policy, and claims experience. The specific products, prices, and coverage terms of the initial batch have not been disclosed.-Fineline Info & Tech
